{
    "id": 10723,
    "fullName": "ERBB3 positive",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "ERBB3 (HER3) positive indicates the presence of the ERBB3 (HER3) gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 2065,
        "geneSymbol": "ERBB3",
        "terms": [
            "ERBB3",
            "c-erbB-3",
            "c-erbB3",
            "ErbB-3",
            "erbB3-S",
            "FERLK",
            "HER3",
            "LCCS2",
            "MDA-BF-1",
            "p180-ErbB3",
            "p45-sErbB3",
            "p85-sErbB3"
        ]
    },
    "variant": "positive",
    "createDate": "08/21/2015",
    "updateDate": "04/25/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 19399,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, CDX-3379 (KTN3379) treatment decreased tumor Erbb3 phosphorylation levels in 83% (10/12) of patients with head and neck squamous cell carcinoma, with 50% or more reduction in 58% (7/12) of patients, and 42% (5/12) patients achieved shrinkage of tumor burden (PMID: 31308059; NCT02473731).",
            "molecularProfile": {
                "id": 10756,
                "profileName": "ERBB3 positive"
            },
            "therapy": {
                "id": 2054,
                "therapyName": "CDX-3379",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16981,
                    "pubMedId": 31308059,
                    "title": "Molecular and Clinical Activity of CDX-3379, an Anti-ErbB3 Monoclonal Antibody, in Head and Neck Squamous Cell Carcinoma Patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31308059"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2980,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ERBB3 (HER3)-positive melanoma cells were sensitive to Canertinib, resulting in decreased metastasis in mouse models (PMID: 25000258).",
            "molecularProfile": {
                "id": 10756,
                "profileName": "ERBB3 positive"
            },
            "therapy": {
                "id": 2136,
                "therapyName": "Canertinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3548,
                    "pubMedId": 25000258,
                    "title": "ERBB3 is required for metastasis formation of melanoma cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25000258"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4565,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Lumretuzumab treatment resulted in stable disease in 21.3% (10/47) of patients with Erbb3 (Her3)-expressing advanced solid tumors (PMID: 26463709).",
            "molecularProfile": {
                "id": 10756,
                "profileName": "ERBB3 positive"
            },
            "therapy": {
                "id": 3546,
                "therapyName": "Lumretuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4617,
                    "pubMedId": 26463709,
                    "title": "First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26463709"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6439,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CDX-3379 (KTN3379) inhibited proliferation of a human breast cancer cell line with autocrine ERBB3 (HER3) signaling in culture (PMID: 26880266).",
            "molecularProfile": {
                "id": 10756,
                "profileName": "ERBB3 positive"
            },
            "therapy": {
                "id": 2054,
                "therapyName": "CDX-3379",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5601,
                    "pubMedId": 26880266,
                    "title": "A Potent HER3 Monoclonal Antibody That Blocks Both Ligand-Dependent and -Independent Activities: Differential Impacts of PTEN Status on Tumor Response.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26880266"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6438,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CDX-3379 (KTN3379) inhibited proliferation and ERBB3 (HER3)-AKT signaling in a human melanoma cell line with autocrine ERBB3 (HER3) signaling in culture (PMID: 26880266).",
            "molecularProfile": {
                "id": 10756,
                "profileName": "ERBB3 positive"
            },
            "therapy": {
                "id": 2054,
                "therapyName": "CDX-3379",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5601,
                    "pubMedId": 26880266,
                    "title": "A Potent HER3 Monoclonal Antibody That Blocks Both Ligand-Dependent and -Independent Activities: Differential Impacts of PTEN Status on Tumor Response.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26880266"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4566,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Lumretuzumab treatment resulted in tumor shrinkage in a patient with Erbb3 (Her3)-expressing triple-receptor negative breast cancer (PMID: 26463709).",
            "molecularProfile": {
                "id": 10756,
                "profileName": "ERBB3 positive"
            },
            "therapy": {
                "id": 3546,
                "therapyName": "Lumretuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4617,
                    "pubMedId": 26463709,
                    "title": "First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26463709"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5528,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Afinitor (everolimus) and Femara inhibited tumor growth in Femara (letrozole)-resistant ESR1-positive breast cancer cell line xenograft models (PMID: 26310543).",
            "molecularProfile": {
                "id": 20964,
                "profileName": "ERBB3 pos ESR1 pos"
            },
            "therapy": {
                "id": 1621,
                "therapyName": "Everolimus + Letrozole",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5081,
                    "pubMedId": 26310543,
                    "title": "Seribantumab, an Anti-ERBB3 Antibody, Delays the Onset of Resistance and Restores Sensitivity to Letrozole in an Estrogen Receptor-Positive Breast Cancer Model.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26310543"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5527,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Seribantumab (MM-12) and Femara (letrozole) inhibited ERBB3 (HER3) activation and tumor growth and delayed onset of resistance to Femara (letrozole) in estrogen receptor (ER)-positive breast cancer xenograft models, and overcame resistance in Femara (letrozole)-resistant models (PMID: 26310543).",
            "molecularProfile": {
                "id": 20964,
                "profileName": "ERBB3 pos ESR1 pos"
            },
            "therapy": {
                "id": 3878,
                "therapyName": "Letrozole + Seribantumab",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5081,
                    "pubMedId": 26310543,
                    "title": "Seribantumab, an Anti-ERBB3 Antibody, Delays the Onset of Resistance and Restores Sensitivity to Letrozole in an Estrogen Receptor-Positive Breast Cancer Model.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26310543"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11935,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, head and neck squamous cell carcinoma cell lines with elevated expression of ERBB3 (HER3) and NRG1 were sensitive to treatment with Tykerb (lapatinib) in culture (PMID: 21840482).",
            "molecularProfile": {
                "id": 23514,
                "profileName": "ERBB3 pos NRG1 pos"
            },
            "therapy": {
                "id": 787,
                "therapyName": "Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9923,
                    "pubMedId": 21840482,
                    "title": "Neuregulin-1-mediated autocrine signaling underlies sensitivity to HER2 kinase inhibitors in a subset of human cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21840482"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6461,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Erbitux (cetuximab) and CDX-3379 (KTN3379) synergized to inhibit tumor growth in human cell line xenograft models of gastric cancer expressing Erbb3 (Her3) and Nrg1 (Hrg) (PMID: 26880266).",
            "molecularProfile": {
                "id": 23514,
                "profileName": "ERBB3 pos NRG1 pos"
            },
            "therapy": {
                "id": 2061,
                "therapyName": "CDX-3379 + Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5601,
                    "pubMedId": 26880266,
                    "title": "A Potent HER3 Monoclonal Antibody That Blocks Both Ligand-Dependent and -Independent Activities: Differential Impacts of PTEN Status on Tumor Response.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26880266"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6454,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CDX-3379 (KTN3379) inhibited tumor growth in xenograft models of head and neck squamous cell carcinoma expressing Erbb3 (Her3) and Nrg1 (Hrg) (PMID: 26880266).",
            "molecularProfile": {
                "id": 23514,
                "profileName": "ERBB3 pos NRG1 pos"
            },
            "therapy": {
                "id": 2054,
                "therapyName": "CDX-3379",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5601,
                    "pubMedId": 26880266,
                    "title": "A Potent HER3 Monoclonal Antibody That Blocks Both Ligand-Dependent and -Independent Activities: Differential Impacts of PTEN Status on Tumor Response.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26880266"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7449,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with Tykerb (lapatinib) led to improved progression-free survival in a patient-derived xenograft (PDX) model of bladder cancer expressing ERBB3 (HER3) and high levels of ERBB2 (HER2) (PMID: 26270481).",
            "molecularProfile": {
                "id": 25511,
                "profileName": "ERBB2 over exp ERBB3 pos"
            },
            "therapy": {
                "id": 787,
                "therapyName": "Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 11054,
                "name": "urinary bladder cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6363,
                    "pubMedId": 26270481,
                    "title": "Development and Characterization of Bladder Cancer Patient-Derived Xenografts for Molecularly Guided Targeted Therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26270481"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8159,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pan-HER reduced Egfr, Erbb2 (Her2), and Erbb3 (Her3) protein levels and inhibited tumor growth in a xenograft model established from an Erbitux (cetuximab)-resistant head and neck squamous cell carcinoma patient (PMID: 27422810).",
            "molecularProfile": {
                "id": 26182,
                "profileName": "EGFR pos ERBB2 pos ERBB3 pos"
            },
            "therapy": {
                "id": 3885,
                "therapyName": "Pan-HER",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6563,
                    "pubMedId": 27422810,
                    "title": "Targeting the HER Family with Pan-HER Effectively Overcomes Resistance to Cetuximab.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27422810"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8305,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, radiation induced expression of EGFR and ERBB3 (HER3) in head and neck squamous cell carcinoma xenograft models demonstrated increased sensitivity when additionally treated with MEHD7945A, resulting in delayed tumor growth and increased DNA double stranded breaks (PMID: 26141946).",
            "molecularProfile": {
                "id": 26226,
                "profileName": "EGFR pos ERBB3 pos"
            },
            "therapy": {
                "id": 4683,
                "therapyName": "Duligotuzumab + Radiotherapy",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6593,
                    "pubMedId": 26141946,
                    "title": "Antitumor Effects of MEHD7945A, a Dual-Specific Antibody against EGFR and HER3, in Combination with Radiation in Lung and Head and Neck Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26141946"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8302,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, head and neck squamous cell carcinoma cells expressing EGFR and ERBB3 (HER3) were sensitive to treatment with MEHD7945A in culture, resulting in decreased cell proliferation (PMID: 26141946).",
            "molecularProfile": {
                "id": 26226,
                "profileName": "EGFR pos ERBB3 pos"
            },
            "therapy": {
                "id": 806,
                "therapyName": "Duligotuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6593,
                    "pubMedId": 26141946,
                    "title": "Antitumor Effects of MEHD7945A, a Dual-Specific Antibody against EGFR and HER3, in Combination with Radiation in Lung and Head and Neck Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26141946"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8303,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, lung cancer cells expressing EGFR and ERBB3 (HER3) demonstrated sensitivity to treatment with MEHD7945A in culture, resulting in decreased cell proliferation (PMID: 26141946).",
            "molecularProfile": {
                "id": 26226,
                "profileName": "EGFR pos ERBB3 pos"
            },
            "therapy": {
                "id": 806,
                "therapyName": "Duligotuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6593,
                    "pubMedId": 26141946,
                    "title": "Antitumor Effects of MEHD7945A, a Dual-Specific Antibody against EGFR and HER3, in Combination with Radiation in Lung and Head and Neck Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26141946"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13090,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Herceptin (trastuzumab) and Tykerb (lapatinib) in ERBB2 (HER2)-receptor positive breast cancer cells resulted in decreased phosphorylation of Erbb3 (Her3) in culture and complete tumor regression in 100% (8/8) of the cell line xenograft models compared to incomplete regression when treated with either agent alone (PMID: 21385943).",
            "molecularProfile": {
                "id": 29003,
                "profileName": "ERBB2 pos ERBB3 pos"
            },
            "therapy": {
                "id": 1414,
                "therapyName": "Lapatinib + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10961,
                    "pubMedId": 21385943,
                    "title": "Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21385943"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 10756,
            "profileName": "ERBB3 positive",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 18589,
            "profileName": "ERBB2 neg ERBB3 pos ESR1 neg PGR neg",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 20964,
            "profileName": "ERBB3 pos ESR1 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 23514,
            "profileName": "ERBB3 pos NRG1 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 25511,
            "profileName": "ERBB2 over exp ERBB3 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26182,
            "profileName": "EGFR pos ERBB2 pos ERBB3 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26226,
            "profileName": "EGFR pos ERBB3 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29003,
            "profileName": "ERBB2 pos ERBB3 pos",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}